Clinical trials: Liver
Alagille Syndrome (ALGS)
A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)
The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time.
- Trial name
- NCT05543174
- Testing
- TAK-625
- Where
- 8 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Takeda
Hepatocellular Carcinoma
Study in Asia of the Combination of TACE With Sorafenib in HCC Patients
TACE possibly plays a significant role in contributing to a subgroup of surviving residual tumor tissue which is characterized by more aggressive biology.
- Trial name
- START (NCT00990860)
- Testing
- doxorubicin, TACE (Transcatheter arterial chemoembolization)
- Where
- 8 sites in Taiwan
- Volunteers
- 36 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatitis B Vaccines
Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Nile Delta of Egypt
More than two billion individuals have serological evidence of hepatitis B virus (HBV) infection worldwide. Of these, 240 million are chronic carriers and approximately 786,000 hepatitis B related deaths occur annually.
- Trial name
- NCT02797782
- Testing
- Detection of anti HBs antibody titer
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sherief Abd-Elsalam
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
- Trial name
- NCT04710524
- Testing
- FM101 150 mg BID, FM101 300 mg BID
- Where
- 12 sites in Hungary, Poland and 1 more
- Volunteers
- 60 people
- Sponsor
- Future Medicine
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary…
- Trial name
- NCT07368023
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Carcinoma, Hepatocellular
Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
To evaluate the safety and efficacy of irinotecan and capecitabine in Asian subjects with inoperable hepatocellular carcinoma.
- Trial name
- NCT00635323
- Testing
- Irinotecan plus capecitabine
- Where
- 9 sites in China, Hong Kong and 2 more
- Volunteers
- 73 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma
The aim of the study was to evaluate the safety and efficacy of using the new formulation (Lipiodol-cisplatin suspension) for TACE in the treatment of HCC as compared to the conventional formulation (Lipiodol-cisplatin emulsion).
- Trial name
- NCT03268499
- Testing
- Lipiodol-based transarterial chemoembolization
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Colorectal Cancer, Metastatic Cancer
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as melphalan, leucovorin, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00103298
- Testing
- FOLFOX regimen, fluorouracil, isolated perfusion
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.
- Trial name
- NCT00136214
- Testing
- MR brain and neuropsychiatric tests
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Beth Israel Deaconess Medical Center
Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Dairy Protien Rich Diet for NAFLD Patients
The overarching aim of this project is to investigate effects of dietary interventions on nonalcoholic fatty liver disease (NAFLD) severity and to delineate the relationship with improvements in metabolic aberrations in liver…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome, Caseins, Whey
- Trial name
- DAIPRO-NAFLD (NCT04841915)
- Testing
- High-Protein Diet, Clinical dietician, Weight loss
- Where
- 2 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
Hepatic Impairment
A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment
The purpose of this study is to determine whether the pharmacokinetic (what the body does to the drug) parameters of telaprevir are altered in patients with moderate hepatic impairment, compared to the pharmacokinetic parameters…
- Trial name
- NCT01600976
- Testing
- telaprevir
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Infectious Diseases BVBA
Hepatocellular Carcinoma
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.
- Trial name
- NCT05842317
- Testing
- Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Hepato Cellular Carcinoma (HCC)
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
The purpose of this study is to test the safety and efficacy of an investigational (experimental) product called BC3402. This product is considered experimental because it is not approved by the U.S.
- Trial name
- NCT06608940
- Testing
- BC3402, Durvalumab, Tremelimumab
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Chronic Hepatitis B
Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine
This study will evaluate the safety and immunogenicity of a novel mixed plasmid DNA (HB-110) combined with an antiviral agent (Adefovir) for the patients with chronic Hepatitis B infection.
- Trial name
- NCT00513968
- Testing
- a mixed plasmid DNA (HB-110), Adefovir
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Genexine, Inc.
Liver Cancer
Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
The most frequently used products in CHE are doxorubicin (36%), cisplatin (31%), and epirubicin (12%). But until recently, there were no obvious reasons to use one product over another.
- Trial name
- IDASPHERE II (NCT02185768)
- Testing
- idarubicin, Dc- Beads 300-500µm
- Where
- 7 sites in France
- Volunteers
- 46 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
This prospective, multicenter, phase II randomized controlled trial compares the efficacy and safety of SBRT combined with systemic therapy versus systemic therapy alone in BCLC stage C hepatocellular carcinoma (HCC).
- Trial name
- NCT07274774
- Testing
- Systemic therapy, Radiotherapy
- Where
- China
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatitis B Virus-Related Hepatocellular Carcinoma
The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy
Hepatitis B virus (HBV) infection is a global health problem, especially in the endemic area like Taiwan, where there are more than 3 million chronic hepatitis B carriers.
- Trial name
- CTEAM (NCT01957618)
- Where
- Taiwan
- Volunteers
- 1,500 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C
Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients
The purpose of this study is to evaluate what happens to hepatitis C virus in response to treatment with pegylated interferon and ribavirin in patients with HCV compared to those with HIV and HCV.
- Trial name
- VK (NCT00703560)
- Volunteers
- 72 people
- Sponsor
- University of Texas Southwestern Medical Center
Liver Cirrhosis
Comparison of Chitosan, Ankaferd and Tranexamic Acid in Dental Extraction in Liver Pre-Transplant Children
The aim of the present study is: To assess the hemostatic effect of chitosan-based dressing, Ankaferd and Tranexamic acid after extraction in children with end stage liver diseases where the: Primary objective: is to evaluate…
- Trial name
- NCT06457360
- Testing
- tranexamic acid, Ankaferd Blood Stopper, Chitosan
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- British University In Egypt
Obesity and Overweight
Kombucha in Overweight and Obese: Live Vs. Pasteurized Effects on Microbiota, Metabolism, and Liver Function
Kombucha, a fermented beverage made from Camellia sinensis tea (black, oolong, or green) with sugar and a symbiotic culture of bacteria and yeast (SCOBY), has gained global attention for its potential health benefits.
- Trial name
- KOMBIOME (NCT06759324)
- Testing
- Live kombucha (non filtered/ non pasteurized), Pasteurized kombucha (non filtered), Control (sparkling water)
- Where
- 2 sites in Portugal
- Volunteers
- 33 people
- Sponsor
- Associação Centro de Apoio Tecnológico Agro Alimentar